https://www.selleckchem.com/pr....oducts/ly-3475070.ht
There is currently no formal consensus on the administration of adjuvant chemotherapy to stage I lung squamous cell carcinoma (LUSC) patients despite the poor prognosis. of adjuvant chemotherapy need to be balanced against the risk of tumour recurrence. #link# Prognostic markers are thus needed to identify those at higher risks and recommend individualised treatment regimens. Clinical and sequencing data of stage I patients were retrieved from the Lung Squamous Cell Carcinoma project of the Cancer Genome Atlas (TCGA) and three tissue
Kao
Komentar
Udio
